Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: A multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium

Journal of Clinical Oncology

Volumn 32, Issue 19, 2014, Pages 2067-2073

  James, Danelle F ^a   Werner, Lillian ^b   Brown, Jennifer R ^b   Wierda, William G ^c   Barrientos, Jacqueline C ^d   Castro, Januario E ^a   Greaves, Andrew ^a   Johnson, Amy J ^e   Rassenti, Laura Z ^a   Rai, Kanti R ^d   Neuberg, Donna ^b   Kipps, Thomas J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Northwell Health   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPHYCOCYANIN; ALLOPURINOL; AMINOTRANSFERASE; ANTIBODY CONJUGATE; B7 ANTIGEN; BETA 2 MICROGLOBULIN; CD19 ANTIGEN; CD20 ANTIGEN; CD38 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHLOROPHYLL A; CREATININE; FAS ANTIGEN; FC RECEPTOR; FLUORESCEIN ISOTHIOCYANATE; GLUCOCORTICOID; HLA DR ANTIGEN; HLA DR5 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; INTERCELLULAR ADHESION MOLECULE 1; LENALIDOMIDE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PERIDININ CHLOROPHYLL A PROTEIN COMPLEX; PROTEIN KINASE ZAP 70; RITUXIMAB; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOGENETICS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; INFUSION RELATED REACTION; LEUKEMIA CELL; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; PROTEIN EXPRESSION; RASH; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; TRISOMY 12; TUMOR FLARE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, FC; RISK FACTORS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84905865264     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.5890     Document Type: Article

References (26)

1. Badoux XC, Keating MJ, Wen S, et al: Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118:3489-3498, 2011
2. Chanan-Khan A, Miller KC, Musial L, et al: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 24:5343-5349, 2006 (Pubitemid 46623164)
3. Chen CI, Bergsagel PL, Paul H, et al: Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 29:1175-1181, 2011
4. Ferrajoli A, Lee BN, Schlette EJ, et al: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291-5297, 2008
5. Andritsos LA, Johnson AJ, Lozanski G, et al: Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 26:2519-2525, 2008
6. Moutouh-de Parseval LA, Weiss L, DeLap RJ, et al: Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 25:5047, 2007 (Pubitemid 350220451)
7. Wierda WG, Cantwell MJ, Woods SJ, et al: CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96:2917-2924, 2000
8. Lapalombella R, Andritsos L, Liu Q, et al: Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 115:2619-2629, 2010
9. Ramsay AG, Johnson AJ, Lee AM, et al: Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118:2427-2437, 2008 (Pubitemid 351949771)
10. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al: Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the antitumour activity of rituximab in vivo. Br J Haematol 140:36-45, 2008 (Pubitemid 350233246)
11. Wu L, Adams M, Carter T, et al: Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14:4650-4657, 2008
12. Lapalombella R, Yu B, Triantafillou G, et al: Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 112:5180-5189, 2008
13. Casak SJ, Lemery SJ, Shen YL, et al: U.S. Food and Drug Administration approval: Rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. Oncologist 16:97-104, 2011
14. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005 (Pubitemid 46211313)
15. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
16. Gribben JG, O'Brien S: Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 29:544-550, 2011
17. Badoux XC, Keating MJ, Wen S, et al: Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 31:584-591, 2013
18. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
19. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006 (Pubitemid 46638957)
20. Rawstron AC, Villamor N, Ritgen M, et al: International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21:956-964, 2007 (Pubitemid 46672072)
21. Extermann M, Overcash J, Lyman GH, et al: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582-1587, 1998 (Pubitemid 28175784)
22. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758, 2002 (Pubitemid 34525533)
23. Rassenti LZ, Huynh L, Toy TL, et al: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:893-901, 2004 (Pubitemid 39096916)
24. Rassenti LZ, Jain S, Keating MJ, et al: Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia Blood 112:1923-1930, 2008
25. Ribatti D, Scavelli C, Roccaro AM, et al: Hematopoietic cancer and angiogenesis. Stem Cells Dev 13:484-495, 2004 (Pubitemid 39473579)
26. Sher T, Miller KC, Lawrence D, et al: Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 51:85-88, 2010